Treatment options for severe chronic hand eczema are limited and carry troublesome adverse effects. Delgocitinib cream had superior efficacy compared with oral alitretinoin for this patient population ...

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib ...

Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand eczema, in two phase 3 trials.

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE). 1 The publication summarizes the results of ...

More than half of patients with steroid-refractory hand eczema responded quickly to a pan-Janus kinase (JAK) inhibitor in a randomized, placebo-controlled trial. After 16 weeks of treatment, patients ...

LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN ...

LEO Pharma has announced positive results from a head-to-head study of its investigational JAK-inhibitor cream, delgocitinib, in adults with severe chronic hand eczema (CHE). Hand eczema is the most ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE). 1 LEO Pharma A/S, a global leader in medical ...